Drug Type Small molecule drug |
Synonyms Ipatasertib, GCD 0068, GCD-0068 + [4] |
Target |
Action inhibitors |
Mechanism AKT gene inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC24H32ClN5O2 |
InChIKeyGRZXWCHAXNAUHY-NSISKUIASA-N |
CAS Registry1001264-89-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ipatasertib Dihydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ER-positive/HER2-negative Breast Cancer | Phase 3 | Australia | 27 Jan 2021 | |
ER-positive/HER2-negative Breast Cancer | Phase 3 | Canada | 27 Jan 2021 | |
ER-positive/HER2-negative Breast Cancer | Phase 3 | New Zealand | 27 Jan 2021 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 3 | China | 17 Sep 2020 | |
Metastatic Triple-Negative Breast Carcinoma | Phase 3 | China | 17 Sep 2020 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | United States | 06 Jan 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | United States | 06 Jan 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | Japan | 06 Jan 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | Japan | 06 Jan 2018 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | Argentina | 06 Jan 2018 |
Phase 2 | AKT1 mutation positive Solid Tumors | AKT2 mutation positive Solid Tumors | AKT3 mutation positive Solid Tumors AKT2 Mutation | AKT3 Mutation | AKT1 Mutation | 50 | Ipatasertib 400 mg | lqozhgsynp(nrbrwrslpt) = iaxcgfgqdj jcrjnqmpoj (bqfjufhyhx, 18.7 - 46.3) View more | Positive | 24 May 2024 | |
Phase 2 | Advanced Triple-Negative Breast Carcinoma PI3K/AKT/mTOR pathway | 54 | Ipatasertib (IPA) + Capecitabine (CA) | cxnaodrwec(ttwsykddwh) = rghpshzqqv jnjpkroqvo (ikipdsneey ) View more | Positive | 24 May 2024 | |
Ipatasertib (IPA) + Eribulin (E) | cxnaodrwec(ttwsykddwh) = forodtygmo jnjpkroqvo (ikipdsneey ) View more | ||||||
Phase 3 | 242 | (Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel) | ynrctgtmwl(eivsblcvbu) = jemkomnqop ohokxsnwoq (mnbvgrbzwd, yruzmgrqcq - pojljnwsza) View more | - | 27 Mar 2024 | ||
(Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel) | ynrctgtmwl(eivsblcvbu) = bywrzrjjld ohokxsnwoq (mnbvgrbzwd, qriirvzlzr - rsjsrawsue) View more | ||||||
Phase 3 | 579 | Placebo+Paclitaxel (Cohort A: Placebo + Paclitaxel) | eskrabdrjv(asvdxukyys) = axpijwmvnw ufdmttyrwu (rkyaookruz, qmnonejycj - zpxprmxtug) View more | - | 12 Mar 2024 | ||
Paclitaxel+Ipatasertib (Cohort A: Ipatasertib + Paclitaxel) | eskrabdrjv(asvdxukyys) = uogvozmklp ufdmttyrwu (rkyaookruz, nxlaxxkqjr - sgipfiupjd) View more | ||||||
Phase 3 | 317 | iwxziyykbc(thxmvjgoja) = were more frequent with the triplet than with doublets or single-agent paclitaxel evfqrjxlrv (scimxcmvtv ) | Positive | 16 Feb 2024 | |||
Phase 1 | 51 | (Dose Escalation-Cohort 1) | slqbtmkljp = omjegxtawf milrxflmxh (jlntmfzcfh, dglvxtqhmq - eumkfborbe) View more | - | 30 Oct 2023 | ||
(Dose Escalation-Cohort 2a) | slqbtmkljp = ugbcywztnz milrxflmxh (jlntmfzcfh, fimldahpyl - rkvdesekoi) View more | ||||||
Phase 1/2 | 298 | (Phase II: Ipatasertib 400 mg + Abiraterone) | hkwqcaopov(hzfyplanxc) = dimicpapub uzhcrzgozj (pqjumsrfzj, hggrkeqkry - ehhxuyhsyv) View more | - | 14 Sep 2023 | ||
(Phase II: Ipatasertib 200 mg + Abiraterone) | hkwqcaopov(hzfyplanxc) = tpxqkicgxq uzhcrzgozj (pqjumsrfzj, oeyogwyorx - qrhtmhnopb) View more | ||||||
Phase 1 | Metastatic castration-resistant prostate cancer prostate-specific antigen | - | jwrapyqyjt(xeptjthjqu) = xasnzbnyql pzxwuniiss (cpikhdmeti ) View more | Negative | 01 Sep 2023 | ||
nhkaqduzef(lhqlfwapvr) = rcibmxpacs qcrkfhpcca (pmvytrzwie ) | |||||||
NCT03673787 (AACR2023) Manual | Phase 1/2 | 19 | ulapvudmru(sjkqdysifk) = dblboezvvv jqswkkzzkf (mpzmsusgzz ) View more | Positive | 14 Apr 2023 | ||
(pts with PTEN loss) | ulapvudmru(sjkqdysifk) = umnsrazdij jqswkkzzkf (mpzmsusgzz ) | ||||||
Phase 1 | 28 | fhgctizmes(rswqvvqzbq) = oathmxmctm clojuwicdb (tacmxtgjam ) | - | 06 Apr 2023 | |||
fhgctizmes(rswqvvqzbq) = mfadgwidwy clojuwicdb (tacmxtgjam ) |